News & Views
Telix today announces that a first patient has been dosed in the Phase 1 ZOLAR[1] trial of TLX300-CDx (89Zr-olaratumab) in patients with advanced, metastatic soft tissue sarcoma (STS) at the…
Read more
Telixtoday announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide…
Read more
News,
Join Telix this week at Europe’s largest urological event, the 40th Annual European Association of Urology Congress (EAU25) being held in Madrid, Spain. Telix’s Phase 3 ProstACT Global study of lead…
Read more
News,
Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by MEB for the detection and…
Read more
Telix today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ‘ANVISA’) has approved Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) the Company’s…
Read more
News,
Telix today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb) and successfully completed first…
Read more
Telix today announces that it has completed the transaction to expand its theranostic pipeline with new candidates targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in…
Read more
Tens of thousands of Australians risk missing out on a new era of cancer treatment if Australia fails to fund and build the medical infrastructure needed to support it, according…
Read more
Telix invites investors to join a webinar showcasing the Company’s late-stage and next-generation radiotherapeutic candidates in urologic oncology. In this education session, Telix and global key opinion leaders will provide an…
Read more
Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational kidney cancer PET imaging agent TLX250-CDx…
Read more